Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The WIL-33 study aims to determine the efficacy, pharmacokinetics, immunogenicity and safety
of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with
severe von Willebrand Disease VWD (defined as screening von Willebrand factor ristocetin
cofactor activity [VWF:RCo] <20%) under the age of 6 years, over a period of 12 months.